PRME Stock Risk & Deep Value Analysis
Prime Medicine Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About PRME Stock
We analyzed Prime Medicine Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran PRME through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
PRME Risk Analysis & Red Flags
What Could Go Wrong
The most significant risk is Prime Medicine's inability to secure adequate financing in 2026-2027 to address its 'going concern' disclosure. With current cash and investments of $149.2M and a Q1 2026 net loss of $49.1M, the company is burning cash rapidly and faces an existential funding crunch that could deplete reserves by early 2027, halting pipeline progression for PM577 and PM647.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
High
Regulatory
Medium
Red Flags
- ⚠
Implied 'going concern' disclosure from the Q1 2026 earnings report, indicating substantial doubt about the company's ability to operate for the next 12 months without additional funding.
- ⚠
Consistently negative EPS (Q1 2026 actual -$0.28) and significant net losses ($49.1M in Q1 2026) with minimal revenue ($0.86M).
- ⚠
Rapid cash burn depleting cash reserves of $149.2M (as of March 31, 2026), necessitating substantial future dilution for existing shareholders.
- ⚠
Lack of material positive news or insider buying activity in the last 90 days to offset the financial concerns.
Upcoming Risk Events
- 📅
Failure to Secure Funding (Before Q1 2027): If Prime Medicine cannot secure additional capital to extend its runway beyond 'into 2027,' it faces severe liquidity issues, potentially leading to asset sales or bankruptcy.
- 📅
Clinical Trial Delays or Failures (2027+): Delays in IND filings for PM577 or PM647, or negative/ambiguous early clinical trial results, would significantly erode investor confidence and valuation.
- 📅
Competitive Technology Emergence (Ongoing): Development of superior or equally effective gene-editing technologies by competitors (e.g., advanced CRISPR, base editing) that could challenge Prime Editing's unique advantages.
When to Reconsider
- 🚪
Exit if the company announces a significant delay in IND filings for PM577 or PM647 beyond Q1 2027.
- 🚪
Sell if the company fails to announce a substantial capital raise (e.g., $100M+) by Q4 2026.
- 🚪
Exit if the cash and investments balance falls below $80M without a clear path to new funding or reduced burn rate.
Unlock PRME Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Prime Medicine Inc (PRME) Do?
Market Cap
$641.19M
Sector
Healthcare
Industry
Biotechnology
Employees
214
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Visit Prime Medicine Inc WebsiteInvestment Thesis
If Prime Medicine successfully secures significant financing (e.g., $150M-$200M) by Q4 2026 to resolve its 'going concern' and concurrently achieves IND filings for PM577 and PM647 in 2026-early 2027, then the market could re-rate the stock from a distressed valuation towards a $3B-$5B market capitalization. This is bullish because the current $0.63B market cap primarily reflects existential financial risk, not the long-term, transformative potential of its Prime Editing technology, creating an asymmetric risk/reward if funding is successfully secured and key pipeline milestones are met.
Is PRME Stock Undervalued?
Unlock the full AI analysis for PRME
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
PRME Price Targets & Strategy
12-Month Target
$7.50
Bull Case
$15.00
Bear Case
$1.50
Valuation Basis
If a capital raise successfully resolves the 'going concern' and key IND milestones are met, the market cap could re-rate to $1.5B-$2.0B post-dilution (approx. 220M shares), yielding a target around $7.50/share.
Entry Strategy
Highly speculative; consider dollar-cost averaging between $2.50-$3.50 only after a financing event is announced, as current price reflects distress.
Exit Strategy
Take profit on significant news-driven rallies (e.g., above $10 after clinical progress). Stop loss at $2.00 if financing fails to materialize or INDs are delayed significantly.
Portfolio Allocation
1-3% for aggressive risk tolerance; not recommended for moderate or conservative portfolios due to existential financial risk.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is PRME Financially Healthy?
Profitability
Operating Margin
-5121.76%
Net Margin
-4917.55%
Return on Equity
-188.82%
Revenue Growth
4.89%
EPS
$-1.26
Balance Sheet
Current Ratio
4.84
Quick Ratio
4.76
Other
Beta (Volatility)
2.30
Does PRME Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
1 Identified
The moat could be highly durable if Prime Editing is proven superior in clinical trials and becomes a standard for precision gene editing. Its ability to correct a broad range of mutations with high specificity and safety would be difficult for competitors to replicate.
Moat Erosion Risks
- •Clinical Failures: Inability to demonstrate safety and efficacy in human trials would invalidate the technology's advantages.
- •Emergence of Superior Technologies: Competitors developing even more advanced or cost-effective gene-editing platforms could erode Prime Medicine's lead.
- •Patent Challenges: Legal challenges to its extensive IP portfolio could weaken its competitive position.
PRME Competitive Moat Analysis
Sign up to see competitive advantages
PRME Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral-to-Bearish, primarily driven by the company's precarious financial position and stock price decline, despite the technological promise.
Institutional Sentiment
Neutral-to-Positive, as indicated by 67% 'Buy' ratings from analysts, but actual institutional buying trends or recent upgrades/downgrades were not available.
Insider Activity (Form 4)
No verified Form 4 insider transactions were found in the provided results for the last 90 days, indicating a lack of recent buying or selling activity.
Options Flow
Normal options activity; no specific unusual put/call ratio or large block trades were available in the provided results.
Earnings Intelligence
Next Earnings
2026-08-06
Surprise Probability
Low
Historical Earnings Pattern
Likely volatile; stock price typically reacts negatively to missed estimates or lack of progress on funding/pipeline, given the speculative nature and high risk.
Key Metrics to Watch
Competitive Position
Top Competitor
NTLA
Market Share Trend
Early stage; currently negligible market share as products are pre-clinical/early clinical. The goal is to establish future market leadership through technological superiority.
Valuation vs Peers
Currently trading at a distressed valuation, making traditional P/E or EV/EBITDA comparisons difficult. Its valuation metrics are likely suppressed compared to more financially stable gene-editing peers (e.g., NTLA, CRSP) that have more advanced clinical pipelines or secured funding.
Competitive Advantages
- •Proprietary Prime Editing Technology: Offers high precision, broad applicability (all 12 base-pair changes), and potentially lower off-target effects compared to traditional CRISPR/Cas9 systems by avoiding double-strand breaks.
- •Strong Intellectual Property: Extensive patent portfolio around Prime Editing ensures a significant competitive moat if the technology is validated.
- •Versatility Across Gene Editing: Potential to address a wider range of genetic mutations and deliver various therapeutic outcomes (insertions, deletions, substitutions) compared to some existing methods.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive PRME Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 Earnings Report (August 6, 2026): Key metrics to watch are cash balance and any updates on financing efforts.
- •Jefferies Global Healthcare Conference Presentation (June 4, 2026): Potential for management to provide insights on pipeline progress or strategic plans, though unlikely to be a major re-rating event.
- •Successful Capital Raise (Estimated Q3/Q4 2026): Resolution of the 'going concern' disclosure with a significant financing round (e.g., $150M-$200M) would de-risk the company's operations.
Medium-Term (6-18 months)
- •IND/CTA Filings for PM577 (Q4 2026 - Q1 2027): Successful filing to initiate clinical trials for the lead program could validate the Prime Editing platform for a specific indication.
- •IND/CTA Filings for PM647 (Q1 2027 - Q2 2027): Progression of the second lead candidate into clinical development, demonstrating pipeline robustness beyond the initial program.
- •Strategic Partnerships (Mid-2027): A significant collaboration or licensing agreement with a major pharmaceutical company, providing non-dilutive capital and external validation of Prime Editing.
Long-Term (18+ months)
- •Positive Phase 1/2 Clinical Trial Data for PM577 (Q4 2027 - 2028): Early human trial results showing safety and efficacy for the lead candidate would be a major re-rating event, potentially increasing market cap towards $5B-$10B.
- •Expanded Pipeline & New Indications (2028-2029): Expansion of Prime Editing to multiple therapeutic areas or diseases, demonstrating platform versatility and broader market applicability.
- •Platform Validation & Market Adoption (2029+): If Prime Editing becomes a preferred gene-editing technology due to its precision and safety profile, it could capture significant market share from CRISPR and other gene therapies.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for PRME?
- ✓
Watch for any official announcement of a significant capital raise (e.g., over $100M) by Q4 2026, as this would be the primary de-risking event.
- ✓
Monitor progress on IND filings for PM577 and PM647; any significant delays beyond Q1 2027 would signal execution issues.
- ✓
Observe the quarterly cash burn rate; a sustained reduction without sacrificing critical R&D, or a significant increase in cash, would be positive.
Bull Case Analysis
Sign up free to see the bull case
Competing with PRME
See how Prime Medicine Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Prime Medicine Inc PRME | $641.2M | 3.0 | — | — | -4917.6% | 4.9% | |
Intellia Therapeutics Inc NTLA | $1.8B | 9.1 | -4.4 | $57.9M | -597.0% | 45.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Prime Medicine Inc Makes Money
Prime Medicine is a biotechnology company focused on developing a new class of precision gene-editing medicines using its proprietary Prime Editing technology. Unlike some other gene-editing methods, Prime Editing aims to directly write new genetic information into DNA without creating double-strand breaks, potentially offering greater precision and safety. Currently, the company generates minimal revenue, primarily operating as a research and development entity, with its business model centered on advancing its therapeutic candidates (like PM577 and PM647) through pre-clinical and clinical development to address various genetic diseases. Future revenue is expected to come from licensing its technology to pharmaceutical partners, collecting royalties on approved therapies, and potentially direct sales of its own approved genetic medicines.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Prime Medicine Inc (PRME)?
As of June 1, 2026, Prime Medicine Inc has a DVR Score of 3.0 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Prime Medicine Inc?
Prime Medicine Inc's market capitalization is approximately $641.2M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Prime Medicine Inc use?
PRME is the ticker symbol for Prime Medicine Inc. The company trades on the NGM.
What is the risk level for PRME stock?
Our analysis rates Prime Medicine Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
Is Prime Medicine Inc's revenue growing?
Prime Medicine Inc has reported revenue growth of 4.9%. The company is growing at a moderate pace.
Is PRME stock profitable?
Prime Medicine Inc has a profit margin of -4917.6%. The company is currently unprofitable.
How often is the PRME DVR analysis updated?
Our AI-powered analysis of Prime Medicine Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on June 1, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for PRME (Prime Medicine Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.